12,372 trials
Pulmonary Tuberculosis
Primary: Combined Failure of Bacteriological Cure and Relapse Within One Year of Completion of Therapy as Defined by Culture Using Solid Media (Lowenstein-Jensen - LJ). — 43; 78…
Breast Cancer
Primary: Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) Related to Bevacizumab, Death, and AEs of Special Interest (AESIs) — 95.4; 57.6; 64.2; 29.7…
Multiple Myeloma
Primary: Time to Progression (TTP) — 6.5; 9.3 Months
Obesity
Primary: Changes in Body Fat Mass — 16790.27; 18223.75; 20174.10; 21474.88 g
Opioid Dependence, on Agonist Therapy
Primary: Primary Endpoints of Retention in Treatment at Days 3 and 15 — 309; 302; 273; 269 participants
Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 84.0; 70.4; 91.7; 88.9 percentage of participants
Arthritis, Rheumatoid
Primary: Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo) — -1.39; -1.37; -1.10 Scores on a scale — p=0.004
Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Comparison of Percentage of Complete Responders — 53.1; 59.2; 46.9; 40.8 percentage of participants — p=0.2344
Diabetes Mellitus, Insulin-Dependent · Hypercholesterolemia
Primary: LDL-C Levels Assessed at Randomization and 6 Months — 128; 87; 126; 133 mg/dL — p=<0.0001
Acquired Immune Deficiency Syndrome Virus
Primary: Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily — 60; 21 percentage change in activated T-cells — p=<0.05
Asthma
Primary: Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period — 0.38; 1.30 L*hr — p=<0.0001
Asthma
Primary: Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period — 0.28; 1.11 L*hr — p=<0.0001
Exercise-Induced Bronchoconstriction (EIB)
Primary: Maximum Percentage Fall From Baseline in Forced Expiratory Volume in 1 Second (FEV1) up to 60 Minutes After the Exercise Challenge — 6.21; 22.38 percentage change from…
Moderate to Severe Plaque-type Psoriasis
Primary: For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement…
Diabetes Mellitus, Type 2
Primary: Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — 0.25; -1.10; -1.30 Percentage of HbA1c in the blood — p=<0.0001